Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage
To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV). This was a retrospective stu...
Gespeichert in:
| Veröffentlicht in: | Journal of ocular pharmacology and therapeutics 2021-12, Vol.37 (10), p.591-596 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 596 |
|---|---|
| container_issue | 10 |
| container_start_page | 591 |
| container_title | Journal of ocular pharmacology and therapeutics |
| container_volume | 37 |
| creator | Chen, Lishuang Qu, Linghui Gui, Qian Wang, Sangsang Mao, Jinghai Fu, Xiangxiang Li, Wendie Wang, Yanyan Yi, Quanyong |
| description | To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
This was a retrospective study of patients who underwent PPV due to vitreous hemorrhage between October 2013 and June 2019 at Ningbo Eye Hospital. The patients who underwent PPV surgery due to PCV-secondary vitreous hemorrhage were included. The primary outcome was the changes in best-corrected visual acuity. The secondary outcome was the central macular thickness.
Compared with the postoperative group (
= 20), the perioperative group (
= 18) showed a smaller number of postoperative anti-VEGF injections (5.1 ± 0.8 vs. 8.0 ± 1.5,
|
| doi_str_mv | 10.1089/jop.2021.0039 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2584781691</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2584781691</sourcerecordid><originalsourceid>FETCH-LOGICAL-c293t-7ea61f3ffe222b1bc1ab9d7014ffd39514734bf368a8bdbaab3abbd01b3c94f63</originalsourceid><addsrcrecordid>eNo9kT1PwzAQhi0E4ntkRR5ZUuw4jZ2xlEKRKtEBWKNzYhOjJA62o6p_iV-JS4HpTrpXz93pQeiKkgklorj9sMMkJSmdEMKKA3RKp1OecM7Sw9gTQRKeC3aCzrz_IIQyktNjdMKynAtSiFP0tdBaVcFjq_GsDyZ5A1-NLTi86GsbGtUaaPGjs5vQ4AeognX43o3vHt8pbZ3C0Nd4poNyeA3O43ULPeA3E1yk2m6LTR8Hwag-7tiYCFnbdjtYU0fsvLFu3-232gFCs_1B_hDs6PFSdda5Bt7VBTrS0Hp1-VvP0evD4mW-TFbPj0_z2Sqp0oKFhCvIqWbxrTRNJZUVBVnUnNBM65oVU5pxlknNcgFC1hJAMpCyJlSyqsh0zs7RzZ47OPs5Kh_KzvhKtfGz3UVlOhUZFzQvaIwm-2jlrPdO6XJwpgO3LSkpd3rKqKfc6Sl3emL--hc9yk7V_-k_H-wbRu-Pyw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2584781691</pqid></control><display><type>article</type><title>Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Chen, Lishuang ; Qu, Linghui ; Gui, Qian ; Wang, Sangsang ; Mao, Jinghai ; Fu, Xiangxiang ; Li, Wendie ; Wang, Yanyan ; Yi, Quanyong</creator><creatorcontrib>Chen, Lishuang ; Qu, Linghui ; Gui, Qian ; Wang, Sangsang ; Mao, Jinghai ; Fu, Xiangxiang ; Li, Wendie ; Wang, Yanyan ; Yi, Quanyong</creatorcontrib><description>To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
This was a retrospective study of patients who underwent PPV due to vitreous hemorrhage between October 2013 and June 2019 at Ningbo Eye Hospital. The patients who underwent PPV surgery due to PCV-secondary vitreous hemorrhage were included. The primary outcome was the changes in best-corrected visual acuity. The secondary outcome was the central macular thickness.
Compared with the postoperative group (
= 20), the perioperative group (
= 18) showed a smaller number of postoperative anti-VEGF injections (5.1 ± 0.8 vs. 8.0 ± 1.5,
< 0.05) and lower frequencies of early hyphema (5.6% vs. 30.0%,
< 0.05), and recurrent vitreous hemorrhage (11.1% vs. 30.0%,
< 0.05). The logarithm of minimal angle resolution (LogMAR) was smaller in the perioperative group compared with the postoperative group at 1 week, 1 month, and 3 months after PPV (
< 0.05), but there were no differences thereafter. Compared with the postoperative group, the perioperative group had thinner fovea at 1 week, 1 month, and 3 months (
< 0.05), but the differences disappeared after 3 months.
In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery.</description><identifier>ISSN: 1080-7683</identifier><identifier>EISSN: 1557-7732</identifier><identifier>DOI: 10.1089/jop.2021.0039</identifier><identifier>PMID: 34678098</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Aged, 80 and over ; Choroidal Neovascularization - surgery ; Female ; Humans ; Male ; Middle Aged ; Postoperative Complications - epidemiology ; Retrospective Studies ; Vascular Endothelial Growth Factors - antagonists & inhibitors ; Visual Acuity ; Vitrectomy - adverse effects ; Vitrectomy - methods ; Vitreous Hemorrhage - surgery</subject><ispartof>Journal of ocular pharmacology and therapeutics, 2021-12, Vol.37 (10), p.591-596</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c293t-7ea61f3ffe222b1bc1ab9d7014ffd39514734bf368a8bdbaab3abbd01b3c94f63</citedby><cites>FETCH-LOGICAL-c293t-7ea61f3ffe222b1bc1ab9d7014ffd39514734bf368a8bdbaab3abbd01b3c94f63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34678098$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Lishuang</creatorcontrib><creatorcontrib>Qu, Linghui</creatorcontrib><creatorcontrib>Gui, Qian</creatorcontrib><creatorcontrib>Wang, Sangsang</creatorcontrib><creatorcontrib>Mao, Jinghai</creatorcontrib><creatorcontrib>Fu, Xiangxiang</creatorcontrib><creatorcontrib>Li, Wendie</creatorcontrib><creatorcontrib>Wang, Yanyan</creatorcontrib><creatorcontrib>Yi, Quanyong</creatorcontrib><title>Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage</title><title>Journal of ocular pharmacology and therapeutics</title><addtitle>J Ocul Pharmacol Ther</addtitle><description>To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
This was a retrospective study of patients who underwent PPV due to vitreous hemorrhage between October 2013 and June 2019 at Ningbo Eye Hospital. The patients who underwent PPV surgery due to PCV-secondary vitreous hemorrhage were included. The primary outcome was the changes in best-corrected visual acuity. The secondary outcome was the central macular thickness.
Compared with the postoperative group (
= 20), the perioperative group (
= 18) showed a smaller number of postoperative anti-VEGF injections (5.1 ± 0.8 vs. 8.0 ± 1.5,
< 0.05) and lower frequencies of early hyphema (5.6% vs. 30.0%,
< 0.05), and recurrent vitreous hemorrhage (11.1% vs. 30.0%,
< 0.05). The logarithm of minimal angle resolution (LogMAR) was smaller in the perioperative group compared with the postoperative group at 1 week, 1 month, and 3 months after PPV (
< 0.05), but there were no differences thereafter. Compared with the postoperative group, the perioperative group had thinner fovea at 1 week, 1 month, and 3 months (
< 0.05), but the differences disappeared after 3 months.
In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Choroidal Neovascularization - surgery</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Postoperative Complications - epidemiology</subject><subject>Retrospective Studies</subject><subject>Vascular Endothelial Growth Factors - antagonists & inhibitors</subject><subject>Visual Acuity</subject><subject>Vitrectomy - adverse effects</subject><subject>Vitrectomy - methods</subject><subject>Vitreous Hemorrhage - surgery</subject><issn>1080-7683</issn><issn>1557-7732</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kT1PwzAQhi0E4ntkRR5ZUuw4jZ2xlEKRKtEBWKNzYhOjJA62o6p_iV-JS4HpTrpXz93pQeiKkgklorj9sMMkJSmdEMKKA3RKp1OecM7Sw9gTQRKeC3aCzrz_IIQyktNjdMKynAtSiFP0tdBaVcFjq_GsDyZ5A1-NLTi86GsbGtUaaPGjs5vQ4AeognX43o3vHt8pbZ3C0Nd4poNyeA3O43ULPeA3E1yk2m6LTR8Hwag-7tiYCFnbdjtYU0fsvLFu3-232gFCs_1B_hDs6PFSdda5Bt7VBTrS0Hp1-VvP0evD4mW-TFbPj0_z2Sqp0oKFhCvIqWbxrTRNJZUVBVnUnNBM65oVU5pxlknNcgFC1hJAMpCyJlSyqsh0zs7RzZ47OPs5Kh_KzvhKtfGz3UVlOhUZFzQvaIwm-2jlrPdO6XJwpgO3LSkpd3rKqKfc6Sl3emL--hc9yk7V_-k_H-wbRu-Pyw</recordid><startdate>202112</startdate><enddate>202112</enddate><creator>Chen, Lishuang</creator><creator>Qu, Linghui</creator><creator>Gui, Qian</creator><creator>Wang, Sangsang</creator><creator>Mao, Jinghai</creator><creator>Fu, Xiangxiang</creator><creator>Li, Wendie</creator><creator>Wang, Yanyan</creator><creator>Yi, Quanyong</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202112</creationdate><title>Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage</title><author>Chen, Lishuang ; Qu, Linghui ; Gui, Qian ; Wang, Sangsang ; Mao, Jinghai ; Fu, Xiangxiang ; Li, Wendie ; Wang, Yanyan ; Yi, Quanyong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c293t-7ea61f3ffe222b1bc1ab9d7014ffd39514734bf368a8bdbaab3abbd01b3c94f63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Choroidal Neovascularization - surgery</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Postoperative Complications - epidemiology</topic><topic>Retrospective Studies</topic><topic>Vascular Endothelial Growth Factors - antagonists & inhibitors</topic><topic>Visual Acuity</topic><topic>Vitrectomy - adverse effects</topic><topic>Vitrectomy - methods</topic><topic>Vitreous Hemorrhage - surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Lishuang</creatorcontrib><creatorcontrib>Qu, Linghui</creatorcontrib><creatorcontrib>Gui, Qian</creatorcontrib><creatorcontrib>Wang, Sangsang</creatorcontrib><creatorcontrib>Mao, Jinghai</creatorcontrib><creatorcontrib>Fu, Xiangxiang</creatorcontrib><creatorcontrib>Li, Wendie</creatorcontrib><creatorcontrib>Wang, Yanyan</creatorcontrib><creatorcontrib>Yi, Quanyong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of ocular pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Lishuang</au><au>Qu, Linghui</au><au>Gui, Qian</au><au>Wang, Sangsang</au><au>Mao, Jinghai</au><au>Fu, Xiangxiang</au><au>Li, Wendie</au><au>Wang, Yanyan</au><au>Yi, Quanyong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage</atitle><jtitle>Journal of ocular pharmacology and therapeutics</jtitle><addtitle>J Ocul Pharmacol Ther</addtitle><date>2021-12</date><risdate>2021</risdate><volume>37</volume><issue>10</issue><spage>591</spage><epage>596</epage><pages>591-596</pages><issn>1080-7683</issn><eissn>1557-7732</eissn><abstract>To compare the clinical effects of postoperative versus perioperative injection of anti-vascular endothelial growth factor (VEGF) drugs before and after pars plana vitrectomy (PPV) in patients with vitreous hemorrhage secondary to polypoidal choroidal vasculopathy (PCV).
This was a retrospective study of patients who underwent PPV due to vitreous hemorrhage between October 2013 and June 2019 at Ningbo Eye Hospital. The patients who underwent PPV surgery due to PCV-secondary vitreous hemorrhage were included. The primary outcome was the changes in best-corrected visual acuity. The secondary outcome was the central macular thickness.
Compared with the postoperative group (
= 20), the perioperative group (
= 18) showed a smaller number of postoperative anti-VEGF injections (5.1 ± 0.8 vs. 8.0 ± 1.5,
< 0.05) and lower frequencies of early hyphema (5.6% vs. 30.0%,
< 0.05), and recurrent vitreous hemorrhage (11.1% vs. 30.0%,
< 0.05). The logarithm of minimal angle resolution (LogMAR) was smaller in the perioperative group compared with the postoperative group at 1 week, 1 month, and 3 months after PPV (
< 0.05), but there were no differences thereafter. Compared with the postoperative group, the perioperative group had thinner fovea at 1 week, 1 month, and 3 months (
< 0.05), but the differences disappeared after 3 months.
In patients with PCV and vitreous hemorrhage, compared with postoperative anti-VEGF, perioperative anti-VEGF could reduce the difficulty of surgery and reduce the occurrence of postoperative complications, but there were no differences in long-term vision and macular thickness after surgery.</abstract><cop>United States</cop><pmid>34678098</pmid><doi>10.1089/jop.2021.0039</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1080-7683 |
| ispartof | Journal of ocular pharmacology and therapeutics, 2021-12, Vol.37 (10), p.591-596 |
| issn | 1080-7683 1557-7732 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2584781691 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Choroidal Neovascularization - surgery Female Humans Male Middle Aged Postoperative Complications - epidemiology Retrospective Studies Vascular Endothelial Growth Factors - antagonists & inhibitors Visual Acuity Vitrectomy - adverse effects Vitrectomy - methods Vitreous Hemorrhage - surgery |
| title | Effects of Anti-Vascular Endothelial Growth Factor Drugs Before and After Pars Plana Vitrectomy in Patients with Polypoidal Choroidal Vasculopathy and Vitreous Hemorrhage |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-19T17%3A51%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20Anti-Vascular%20Endothelial%20Growth%20Factor%20Drugs%20Before%20and%20After%20Pars%20Plana%20Vitrectomy%20in%20Patients%20with%20Polypoidal%20Choroidal%20Vasculopathy%20and%20Vitreous%20Hemorrhage&rft.jtitle=Journal%20of%20ocular%20pharmacology%20and%20therapeutics&rft.au=Chen,%20Lishuang&rft.date=2021-12&rft.volume=37&rft.issue=10&rft.spage=591&rft.epage=596&rft.pages=591-596&rft.issn=1080-7683&rft.eissn=1557-7732&rft_id=info:doi/10.1089/jop.2021.0039&rft_dat=%3Cproquest_cross%3E2584781691%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2584781691&rft_id=info:pmid/34678098&rfr_iscdi=true |